Celgene nabs FDA approval for blockbuster hopeful anemia med Reblozyl

celgene
Celgene's Reblozyl nabbed an FDA approval to treat anemia Friday. (Celgene)

Bristol-Myers Squibb's $74 billion pending pickup of Celgene has notched a win already with an FDA approval for JAK med Inrebic. Now, the consummation has grabbed another victory with an approval for a Celgene blood disease candidate––and it could spell blockbuster sales ahead.

The FDA Friday approved Celgene's Reblozyl (luspatercept), a novel erythroid maturation agent used to treat anemia in patients with beta thalassemia who require regular red blood cell transfusions. Though these transfusions are a lifesaving treatment, they can eventually lead to iron overload that can cause organ failure and shorten a patient’s life span. 

Reblozyl, co-developed with Cambridge, Massachusetts-based biotech Acceleron, is now the first FDA-approved treatment for anemia in beta thalassemia. The drug is expected to be ready for sale in one week, Celgene said. 

Webinar

Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.

The FDA's nod was based on phase 3 data showing Reblozyl significantly increased the number of patients who required fewer blood transfusions over placebo in a 24-week period.

Celgene's drug will come with label warnings for thrombosis, or blood clots, hypertension and embryo-fetal toxicity, the company said. Serious adverse effects, including cerebrovascular accident and deep vein thrombosis, were reported in 1% of trial patients, and one patient reportedly died during clinical testing due to an unconfirmed case of acute myeloid leukemia, Celgene said.

RELATED: In a much-needed positive for BMS, Celgene gains FDA review for blockbuster hopeful

Reblozyl comes with blockbuster hopes, with Jefferies analysts forecasting $2 billion in peak annual sales for the drug if it gets a positive nod from the FDA in April to treat myelodysplastic syndromes.